UC San Diego Health Moores Cancer Center | Strategic Alliance Partners

Lyudmila A. Bazhenova, MD, discusses upcoming inhibitors of interest in the combination therapy space for patients with KRAS G12C–mutant NSCLC.

Expert panelists briefly reflect on clinical trial data with CDK4/6 inhibitors in metastatic castration-resistant prostate cancer and how their role in this setting might evolve.

A broad discussion on emerging therapeutic targets in metastatic castration-resistant prostate cancer and where they may fall within the treatment landscape.

Key opinion leaders share insight to novel combination strategies and clinical trials focused on radioligand therapy in metastatic castration-resistant prostate cancer.

Continuing their segment on radioligand therapy in metastatic castration-resistant prostate cancer, panelists highlight data behind use of radium-223.

Hemali Batra-Sharma, MD, discusses a single-institution, retrospective clinicopathologic analysis of patients with metaplastic breast cancer, findings from which were presented at the 2023 ASCO Annual Meeting.

Focused discussion on the role of lutetium-177–PSMA-617 as radioligand therapy in patients with metastatic castration-resistant prostate cancer.

Key opinion leaders in metastatic castration-resistant prostate cancer management review a subset of clinical trials focused on combination strategies with PARP inhibitors.

Moving on to discuss metastatic castration-resistant prostate cancer, panelists highlight the evolving role of PARP inhibition in this setting.

Comprehensive insight to key treatment modalities for patients with nonmetastatic castration-resistant prostate cancer and how to select amongst them.

A brief conversation on negative clinical trial readouts and how they may help to inform optimal treatment pathways for patients with metastatic hormone-sensitive prostate cancer.

Following their discussion on systemic therapy, expert panelists consider the value of locoregional therapy for a subset of patients with metastatic hormone-sensitive prostate cancer.

Sohail Dhanji, MD, discusses the effect of preoperative hypertension on survival outcomes in patients undergoing nephroureterectomy for upper tract urothelial carcinoma, and the importance of hypertension control in this population.

The bispecific antibody petosemtamab delivered responses with a manageable safety profile in patients with advanced head and neck squamous cell carcinoma.

Ramez N. Eskander, MD, highlights the potential implications of the NRG GY018 trial as well as safety and efficacy results from the trial.

Presenters from the 2023 SGO Annual Meeting share their insights on the treatment of patients with gynecologic cancers.

Jennifer M. Matro, MD, discusses the real-world implications and uptake of the HER2CLIMB regimen, other trials investigating tucatinib-based regimens in HER2-positive metastatic breast cancer, and how approaches differ between early-stage and metastatic hormone receptor–positive/HER2-negative breast cancer.

Ramez N. Eskander, MD, discusses findings from the phase 3 NRG GY018 trial of pembrolizumab plus chemotherapy in patients with endometrial cancer.

Gregory Botta, MD, PhD, discusses the diagnosis and treatment of patients with esophageal squamous cell carcinoma.

Rana R. McKay, MD, discusses the pros and cons of utilizing triplet therapy in the frontline treatment of patients with renal cell carcinoma.

Rana R. McKay, MD, discusses the potential impact of triplet therapies in the treatment paradigm for metastatic renal cell carcinoma and identifies several other areas for further study.

Pratibha Binder, MD, discusses how the introduction of novel immune checkpoint inhibitors into frontline treatment strategies could ameliorate unmet needs in endometrial cancer.

Cheryl Saenz, MD, discusses the need for ongoing research efforts in cervical cancer.

Rana R. McKay, MD, discusses four key trials that have advanced the frontline treatment of metastatic renal cell carcinoma in the modern era.

Pratibha Binder, MD, discusses key trials improving the array of treatment options for patients with endometrial cancer.

Rana R. McKay, MD, discusses the evolution of frontline treatment options for metastatic RCC, and the key clinical trials that have shifted the treatment paradigms in metastatic castration-resistant prostate cancer, nonmetastatic castration-resistant prostate cancer, and advanced prostate cancer.

Gregory Botta, MD, PhD, discusses the rationale for investigating CT041 in patients with advanced gastric and pancreatic cancers in a phase 1b trial.

CT041, a Claudin18.2–specific CAR T-cell therapy, demonstrated a manageable safety profile in patients with previously treated, CLDN18.2-positive advanced gastric/gastroesophageal junction cancer, with a majority of patients achieving partial response or stable disease.

Jyoti Mayadev, MD, discusses the phase 1 NRG-GY017 trial evaluating atezolizumab given as an immune primer or concurrently with extended field chemoradiation in patients with locally advanced, node-positive cervical cancer.

Rana R. McKay, MD, discusses findings from a real-world study on genomic alterations of metastases in renal cell carcinoma, the rationale of the phase 3 COSMIC-313 trial in patients with previously untreated advanced or metastatic RCC, plus findings from the phase 1/2 COMRADE trial in patients with metastatic castration-resistant prostate cancer.